McMaster University

McMaster University

Faculty of
Health Sciences

NCE confirms AllerGen funding to 2019

Published: November 27, 2015
Judah Denburg
Dr. Judah Denburg, scientific director and CEO, AllerGen, and professor, Department of Medicine

AllerGen will receive ongoing federal funding through the Networks of Centres of Excellence (NCE) program to continue its work in allergic disease research, training and innovation to 2019.

"After a review by the NCE's international expert panel on September 17, 2015, AllerGen was deemed eligible for continued funding because it met the NCE's standards for excellence in performance of all five NCE mandate areas — research, networking and partnership, capacity building/training, knowledge and technology exchange and exploitation and management," says Dr. Judah Denburg, scientific director and CEO of AllerGen and a professor of medicine of McMaster's Michael G. DeGroote School of Medicine.

"Over the next four years, working closely with partners, stakeholders and our host institution, McMaster University, we will complete our research and focus on translating and commercializing key findings to promote earlier diagnosis, disease interception, better treatment and optimal outcomes for Canadians with allergic diseases."

McMaster President Patrick Deane is a member of AllerGen's Board of Directors.

"AllerGen has continued to advance asthma and allergy research, knowledge mobilization and commercialization in Canada, with high-impact findings that have captured the attention of the scientific and clinical community, industry and the general public," he said. "It is ensuring the future of the field by training a new generation of researchers and clinician-scientists."

Among other ties to its host university, AllerGen supports the Canadian Healthy Infant Longitudinal Development (CHILD) study, headed by McMaster professor Malcolm Sears, and the Clinical Investigator Collaborative led by professor Paul O'Byrne, chair of the Department of Medicine.

The Canadian government's award to AllerGen from 2005 to 2019 totals $74.4 million. The ongoing funding was confirmed as part of a review process that assessed AllerGen's achievements midway through its second seven-year term.

Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0